Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Emergence Delirium 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Delirium 1

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × remimazolam × 1 year × Clear all
NCT07351474 2026-01-20

Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy

The First Affiliated Hospital with Nanjing Medical University

Phase NA Not yet recruiting
170 enrolled
Gastrointestinal

Emergence Delirium, Stomach Neoplasms

NCT04532606 2025-07-30

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Peking University First Hospital

Phase 4 Recruiting
1,128 enrolled
Genitourinary

Emergence Delirium, Urinary Bladder Neoplasms, Delirium

Data powered by HemOnc (CC BY 4.0) Colophon âš¡